Dosage Regimens of Antibacterials: Implications of a Pharmacokinetic/Pharmacodynamic Model

Clinical Drug Investigation

Volumn 11, Issue 4, 1996, Pages 229-239

  Bouvier D'Yvoire, Michel J Y ^a   Maire, Pascal H ^b  

^a SANOFI   (France)

^b HOSPICES CIVILS DE LYON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; ANTIINFECTIVE AGENT; TICARCILLIN; TOBRAMYCIN;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; ARTICLE; CONCENTRATION RESPONSE; DRUG EFFICACY; DRUG HALF LIFE; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SIMULATION;

EID: 0030009518     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-199611040-00006     Document Type: Article

References (23)

1. Ebert SC, Craig WA. Pharmacodynamic properties of antibiotics: application to drug monitoring and dosage regimen design. Infect Control Hosp Epidemiol 1990; 6: 319-26
2. Craig WA, Ebert SC. Killing and regrowth of bacteria in vitro: a review. Scand J Infect Dis 1991; Suppl. 74: 63-70
3. Bergan T, Carlsen IB. Bacterial kill rates of amoxycillin and ampicillin at exponentially diminishing concentrations simulating in vivo conditions. Infection 1980; 8 Suppl. 1: 103S-8S
4. Shah PM, Ghahremani M, Gorres FJ, et al. Bactericidal activity of antimicrobials in the dynamic kill-curve model. J Drug Develop 1988; 1 Suppl. 3: 35-47
5. Garrett ER. Kinetics of antimicrobials action. Scand J Infect Dis 1978; 14: 54-85
6. Navashin SM, Fomina IP, Firsov AA, et al. A dynamic model for in vitro evaluation of antimicrobial action by simulation of the pharmacokinetic profiles of antibiotics. J Antimicrob Chemother 1989; 23: 389-99
7. Briceland LL, Pasko MT, Mylotte JM. Serum bacterial rate as a measure of antibiotic interactions. Antimicrob Agents Chemother 1987; 31: 679-85
8. Tisdale JE, Pasko MT, Mylotte JM. Antipseudomonal activity of simulated infusions of gentamicin alone or with piperacillin assessed by serum bactericidal rale and area under the killing curve. Antimicrob Agents Chemother 1989; 33: 1500-5
9. Drusano GL. Human pharmacodynamics of beta-lactams, aminoglycosides and their combination. Scand J Infect Dis 1991; Suppl. 74: 235-48
10. Zhi J, Nightingale CH, Quintiliani R. Microbial pharmacodynamics of piperacillin in neutropenic mice with systemic infection due to Pseudomonas aeruginosa. J Pharmacokinet Biopharm 1988; 16: 355-75
11. Mentré F. Analyse de la relation dose-effet par les modèles de population. In: Chastang C, Pons G, Regnier B, editors. Méthodes nouvelles en pharmacologie cliníque pédiatrique. Paris: Springer-Verlag, 1992: 69-88
12. Blaser J, Stone BB, Zinner SH. Efficacy of intermittent versus continuous administration of netilmicin in a two-compartment in vitro model. Antimicrob Agents Chemother 1985; 27: 343-9
13. Blaser J, Stone BB, Groner MC, et al. Comparative study wit enoxacin and netilmícin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob Agents Chemother 1987; 31: 1054-60
14. Gerber AU, Wiprächtiger P, Stettler-Spichiger U, et al. Constant infusions vs. intermittent doses of gentamicin against Pseudomonas aeruginosa in vitro. J Infect Dis 1982; 145: 554-60
15. Vogelman BS, Craig WA. Postantibiotic effects. J Antimicrob Chemother 1985; 15 Suppl. A: 37-46
16. Leggett JE, Ebert S, Fantin B, et al. Comparative dose-effect relations at several dosing intervals for beta-lactams, aminoglycoside and quinolone antibiotics against Gram-negative bacilli in murine thigh-infection and pneumonitis models. Scand J Infect Dis 1991; Suppl. 74: 179-84
17. Giuliano RA, Verpooten GA, Verbist L, et al. In vivo uptake kinetics of aminoglycosides in the kidney cortex of rats. J Pharmacol Exp Ther 1986; 236: 470-5
18. Verpooten GA, Giuliano RA, Verbist L, et al. Once-daily dosing decreases renal accumulation of gentamicin and netilmicin. Clin Pharmacol Ther 1989; 45: 22-7
19. Mattie H, Craig WA, Péchère JC. Determinants of efficacy and toxicity of aminoglycosides. J Antimicrob Chemother 1989; 24: 281-93
20. Barclay ML, Begg EJ, Hickling KG. What is the evidence for once-daily aminoglycoside therapy? Clin Pharmacokinet 1994; 27: 32-48
21. Zhanel GG, Craig WA. Pharmacokinetic contributions to postantibiotic effects. Focus on aminoglycosides. Clin Pharmacokinet 1994; 27: 377-92
22. Daikos GL, Jackson GG, Lolans VT, et al. Adaptive resistance to aminoglycoside antibiotics from first exposure down-regulation. J Infect Dis 1990; 162: 414-20
23. Daikos GL, Lolans VT, Jackson GG. First-exposure adaptive resistance to aminoglycoside antibiotics in vivo with meaning for optimal clinical use. Antimicrob Agents Chemother 1991; 35: 117-23